Eun Yang
Stock Analyst at Jefferies
(0.62)
# 3,792
Out of 4,736 analysts
46
Total ratings
37.04%
Success rate
-25.9%
Average return
Main Sectors:
Stocks Rated by Eun Yang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UTHR United Therapeutics | Maintains: Buy | $315 → $432 | $367.97 | +17.40% | 8 | Sep 23, 2024 | |
| AVTE Aerovate Therapeutics | Downgrades: Hold | $65 → $2 | $2.55 | -21.57% | 3 | Jun 17, 2024 | |
| TSHA Taysha Gene Therapies | Assumes: Buy | $2 → $8 | $1.53 | +422.88% | 2 | May 14, 2024 | |
| ATXS Astria Therapeutics | Maintains: Buy | $22 → $27 | $7.57 | +256.67% | 2 | Mar 25, 2024 | |
| RLYB Rallybio | Downgrades: Hold | $7 → $1.5 | $0.89 | +67.79% | 2 | Feb 7, 2024 | |
| BBIO BridgeBio Pharma | Downgrades: Hold | $24 → $33 | $36.08 | -8.54% | 1 | Jul 18, 2023 | |
| BMEA Biomea Fusion | Downgrades: Hold | $36 → $28 | $4.25 | +558.82% | 2 | Jun 26, 2023 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $27 | $22.00 | +22.73% | 1 | Mar 29, 2023 | |
| GNSS Genasys | Maintains: Outperform | $6 → $7 | $2.88 | +143.06% | 1 | Feb 10, 2023 | |
| CVAC CureVac | Upgrades: Buy | n/a | $4.14 | - | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $2.91 | +759.11% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $525 → $75 | $1.15 | +6,421.74% | 1 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $84 | $111.96 | -24.97% | 3 | Aug 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $1.53 | +1,533.99% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $6.57 | - | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $16.46 | +112.64% | 1 | Jun 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $220 | $274.81 | -19.94% | 3 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $38 → $31 | $13.56 | +128.61% | 5 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $310 | $140.98 | +119.89% | 3 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $80 | $92.96 | -13.94% | 3 | Jul 11, 2017 |
United Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $315 → $432
Current: $367.97
Upside: +17.40%
Aerovate Therapeutics
Jun 17, 2024
Downgrades: Hold
Price Target: $65 → $2
Current: $2.55
Upside: -21.57%
Taysha Gene Therapies
May 14, 2024
Assumes: Buy
Price Target: $2 → $8
Current: $1.53
Upside: +422.88%
Astria Therapeutics
Mar 25, 2024
Maintains: Buy
Price Target: $22 → $27
Current: $7.57
Upside: +256.67%
Rallybio
Feb 7, 2024
Downgrades: Hold
Price Target: $7 → $1.5
Current: $0.89
Upside: +67.79%
BridgeBio Pharma
Jul 18, 2023
Downgrades: Hold
Price Target: $24 → $33
Current: $36.08
Upside: -8.54%
Biomea Fusion
Jun 26, 2023
Downgrades: Hold
Price Target: $36 → $28
Current: $4.25
Upside: +558.82%
Enliven Therapeutics
Mar 29, 2023
Initiates: Buy
Price Target: $27
Current: $22.00
Upside: +22.73%
Genasys
Feb 10, 2023
Maintains: Outperform
Price Target: $6 → $7
Current: $2.88
Upside: +143.06%
CureVac
Jan 9, 2023
Upgrades: Buy
Price Target: n/a
Current: $4.14
Upside: -
Nov 14, 2022
Initiates: Buy
Price Target: $25
Current: $2.91
Upside: +759.11%
Sep 22, 2022
Maintains: Buy
Price Target: $525 → $75
Current: $1.15
Upside: +6,421.74%
Aug 22, 2022
Maintains: Buy
Price Target: $78 → $84
Current: $111.96
Upside: -24.97%
Nov 2, 2021
Initiates: Buy
Price Target: $25
Current: $1.53
Upside: +1,533.99%
Jul 12, 2021
Initiates: Buy
Price Target: n/a
Current: $6.57
Upside: -
Jun 22, 2021
Initiates: Buy
Price Target: $35
Current: $16.46
Upside: +112.64%
Jul 27, 2018
Maintains: Buy
Price Target: $200 → $220
Current: $274.81
Upside: -19.94%
Nov 3, 2017
Maintains: Hold
Price Target: $38 → $31
Current: $13.56
Upside: +128.61%
Jul 11, 2017
Assumes: Hold
Price Target: $310
Current: $140.98
Upside: +119.89%
Jul 11, 2017
Assumes: Hold
Price Target: $80
Current: $92.96
Upside: -13.94%